| __timestamp | Amgen Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 4699000000 | 6620800000 |
| Thursday, January 1, 2015 | 4846000000 | 6533000000 |
| Friday, January 1, 2016 | 5062000000 | 6452000000 |
| Sunday, January 1, 2017 | 4870000000 | 6588100000 |
| Monday, January 1, 2018 | 5332000000 | 5975100000 |
| Tuesday, January 1, 2019 | 5150000000 | 6213800000 |
| Wednesday, January 1, 2020 | 5730000000 | 6121200000 |
| Friday, January 1, 2021 | 5368000000 | 6431600000 |
| Saturday, January 1, 2022 | 5414000000 | 6440400000 |
| Sunday, January 1, 2023 | 6179000000 | 6941200000 |
| Monday, January 1, 2024 | 7096000000 | 8593800000 |
Cracking the code
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Eli Lilly and Amgen have demonstrated distinct approaches to managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Eli Lilly consistently outpaced Amgen, with SG&A expenses peaking at approximately $6.94 billion in 2023, marking a 5% increase from 2014. In contrast, Amgen's SG&A expenses grew by 31% over the same period, reaching around $6.18 billion in 2023. This divergence highlights Eli Lilly's steady financial strategy compared to Amgen's more dynamic approach. As these giants continue to innovate, their financial maneuvers offer valuable insights into their operational priorities and market positioning.
Gross Profit Comparison: Eli Lilly and Company and Amgen Inc. Trends
Eli Lilly and Company and Novo Nordisk A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Opthea Limited
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Xencor, Inc.
Selling, General, and Administrative Costs: Amgen Inc. vs Sanofi
Operational Costs Compared: SG&A Analysis of Amgen Inc. and BioMarin Pharmaceutical Inc.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Novavax, Inc.